Luteolin is a novel p90 ribosomal S6 kinase (RSK) inhibitor that suppresses Notch4 signaling by blocking the activation of Y-box binding protein-1 (YB-1)
Kristen M. Reipas(University of British Columbia), Sandra E. Dunn(University of British Columbia)
Cited by 60
Related Papers
Phosphorylated Insulin-Like Growth Factor-I/Insulin Receptor Is Present in All Breast Cancer Subtypes and Is Related to Poor Survival
|Cancer Research|2008|407
Y-box binding protein-1 serine 102 is a downstream target of p90 ribosomal S6 kinase in basal-like breast cancer cells
|Breast Cancer Research|2008|164
Celecoxib analogues disrupt Akt signaling, which is commonly activated in primary breast tumours
|Breast Cancer Research|2005|93